TICKERNERD
Menu
HHSHHSIndustrials · Conglomerates

HHS Stock Forecast: Harte-Hanks, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$4.20
−1.87% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$31.3M
Ticker Nerd rank
32 / 100
Median analyst target
—
Analysts covering
1
Revenue$38.0M−1.7% y/y
Operating income−$4.3M
Net income−$5.0M
Free cash flow−$2.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.2%
1M
+68.7%
YTD
+39.5%
1Y
+12.9%
From 52W high
−3.2%
From 52W low
+110.0%
$2.00
$4.34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HHS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Harte-Hanks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Size
85
Momentum
52
Issuance
40
Quality
37
Value
33
Volatility
28
Revisions
25
Growth
9

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HHS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HHS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$2.50$3.00$3.50$4.00$4.50Oct 25Jan 26Apr 26Jul 26HHS

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Nov 2017Noble Capital MarketsUpgradeBuy—
14 Mar 2016BMO CapitalDowngradeMarket Perform—
8 Dec 2015Singular ResearchInitiatesBuy—
21 July 2015BMO CapitalUpgradeOutperform—
30 May 2014BMO CapitalDowngradeMarket Perform—
21 Oct 2013Noble Capital MarketsDowngradeHold—
4 Oct 2013BMO CapitalUpgradeOutperform—
26 Apr 2013Noble Capital MarketsUpgradeBuy—
1 Feb 2013BMO CapitalMaintainsMarket Perform—
1 Feb 2013Noble Capital MarketsDowngradeHold—
26 Oct 2012BMO CapitalMaintainsMarket Perform—
26 Oct 2012Noble Capital MarketsUpgradeBuy—
18 July 2012Noble Capital MarketsDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HHS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HHS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Harte-Hanks, Inc. returned +12.9% against +17.5% for the S&P 500, dividends included.

HHS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Oct 25Jan 26Apr 26Jul 26HHSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HHS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Harte-Hanks, Inc. (HHS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.3×

Cheaper than 69% of US stocks

Price / sales
0.2×

Cheaper than 93% of US stocks

Price / book
2.0×

Cheaper than 45% of US stocks

EV / EBITDA
−125.7×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
−1.7%

Higher than 25% of US stocks

Earnings growth (YoY)
−10.3%

Higher than 26% of US stocks

Gross margin
67.1%

Higher than 80% of US stocks

Operating margin
−12.2%

Higher than 24% of US stocks

Net margin
−3.7%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−30.4%

Higher than 27% of US stocks

Return on assets
−3.4%

Higher than 34% of US stocks

Dividend yield
81.0%

Higher than 98% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Harte-Hanks, Inc. (HHS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Harte-Hanks, Inc. has a market value of $31.3M and an enterprise value of $50.2M.

  • Revenue in the twelve months to 30 June 2026: $154.6M. The latest quarter shrank 1.7% year on year.

  • Net income over the same four quarters: −$5.7M, a −3.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.76.

  • Free cash flow in the twelve months to 30 June 2026: −$1.4M.

  • Shares outstanding: 7.5M.

  • Trailing P/E: 2.3×; forward P/E: 3.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 80.95%, paying out 0% of earnings.

  • Harte-Hanks, Inc. employs 1,719 people — $90K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

HHS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelConglomerates
CompanyMarket capTKN rank
HHSHarte-Hanks, Inc.$31.3M
32
GPUSHyperscale Data, Inc.$29.8M
10
LGPSLogProstyle, Inc.$19.6M
45
AIRTAir T, Inc.$82.8M
41
PLAGPlanet Green Holdings Corp.$10.2M
39
BOOMDMC Global, Inc.$130.6M
55
TUSKMammoth Energy Services, Inc.$149.3M
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Harte-Hanks, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HHS news & analysis

HHS plans new FDA deputy commissioner roles for technology and drugs, sources say

CNBC · 25 Aug 2026neutral

The Department of Health and Human Services plans to create two new FDA deputy commissioner roles covering technology and drugs, according to CNBC. The new positions would report to the nominee for FDA commissioner, Heidi Overton, whose confirmation is still pending in the Senate.

Why it matters — HHS watchers would follow this because the creation of new FDA leadership roles signals organizational restructuring at the agency under the incoming administration.

Shareholder Alert: Ademi LLP investigates whether Harte Hanks, Inc. is obtaining a Fair Price for Public Shareholders

PRNewsWire · 14 Aug 2026negative

Ademi LLP announced it is investigating Harte Hanks, Inc. for possible breaches of fiduciary duty and other violations of law related to the company's recently announced transaction with Star Equity. The firm is seeking additional shareholders to join the investigation.

Why it matters — A shareholder law firm has opened a fiduciary-duty investigation into the proposed Star Equity transaction, which could bring scrutiny to the deal's terms and fairness for public shareholders.

HHS Stock Alert: Halper Sadeh LLC is Investigating Whether Harte Hanks, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 14 Aug 2026negative

Halper Sadeh LLC, an investor rights law firm, is investigating whether Harte Hanks, Inc. is obtaining a fair price in its proposed sale to Star Equity Holdings, Inc. Under the deal, Harte Hanks shareholders may choose $5.00 per share in cash or 0.50 shares of Star Equity preferred stock per Harte Hanks share.

Why it matters — The investigation raises the possibility that Harte Hanks shareholders may not be receiving adequate consideration in the proposed transaction.

Star Equity Holdings Enters Into Merger Agreement to Acquire Harte Hanks

GlobeNewsWire · 14 Aug 2026positive

Star Equity Holdings has entered into a merger agreement to acquire Harte Hanks, a global customer experience and business process outsourcing company. Harte Hanks stockholders will receive $5.00 per share, consisting of cash and Star preferred stock.

Why it matters — Harte Hanks stockholders will receive a defined $5.00 per share offer as the company is acquired by Star Equity Holdings, expanding Star's business services platform and enhancing revenue diversity.

Harte Hanks Enters Definitive Agreement to Be Acquired by Star Equity Holdings for $5.00 Per Share

Accesswire · 14 Aug 2026positive

Harte Hanks has entered into a definitive merger agreement to be acquired by Star Equity Holdings for $5.00 per share, representing approximately $38.4 million in aggregate equity value. The transaction will be paid 50% in cash and 50% in Star Equity 10% preferred stock, and has been unanimously approved by Harte Hanks' Board of Directors.

Why it matters — The acquisition at a roughly 100% premium to Harte Hanks' unaffected share price means shareholders are being offered significantly more than the stock's recent market value.

FAQ

Frequently asked questions about HHS stock

Is HHS stock a buy right now?

Of the 1 analysts covering Harte-Hanks, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Harte-Hanks, Inc. 32 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HHS?

As at 12 Sept 2026, Harte-Hanks, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

What is the HHS stock forecast for 2030?

No analyst covering Harte-Hanks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HHS are extrapolating price history, which says nothing about the business.

How has HHS stock performed over the past year?

Harte-Hanks, Inc. returned +12.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Harte-Hanks, Inc. do?

Harte Hanks Inc. is a global customer experience and marketing services company that helps brands engage, serve, and retain customers through integrated solutions.

What is the latest news on HHS?

The most recent item we track (CNBC, 25 Aug 2026): "HHS plans new FDA deputy commissioner roles for technology and drugs, sources say". The Department of Health and Human Services plans to create two new FDA deputy commissioner roles covering technology and drugs, according to CNBC. The new positions would report to the nominee for FDA commissioner, Heidi Overton, whose confirmation is still pending in the Senate.

Company

About Harte-Hanks, Inc.

Harte Hanks Inc. is a global customer experience and marketing services company that helps brands engage, serve, and retain customers through integrated solutions. Harte Hanks Inc. focuses on marketing services, customer care, and fulfillment and logistics, combining data-driven strategy with creative execution and operational support. Its offerings include digital and direct marketing, analytics, audience targeting, contact center services, e-commerce support, print and mail fulfillment, product distribution, and logistics optimization. The company serves clients across industries such as healthcare, financial services, retail, technology, automotive, entertainment, and consumer goods. Harte Hanks Inc. plays a role in the financial market as a diversified business services provider with recurring client relationships and broad exposure to customer engagement, marketing operations, and supply-chain-related services.

CEO Mr. Kirk A. Davis · 1,719 employees · United States · https://www.hartehanks.com